Functional Polymorphisms of Folate-metabolizing Enzymes in Relation to Homocysteine Concentrations in Systemic Lupus Erythematosus

Overview

Journal J Rheumatol

Specialty Rheumatology

Date 2008 Sep 12

PMID 18785313

Citations 12

Authors

Carolyn M Summers

Andrew J Cucchiara

Eleni Nackos

Andrea L Hammons

Elisabeth Mohr

Alexander S Whitehead

Joan M Von Feldt

Affiliations

Soon will be listed here.

Abstract

Objective: To determine if functional polymorphisms of folate/homocysteine pathway enzymes are associated with homocysteine concentrations and/or coronary artery calcification (CAC) scores in patients with systemic lupus erythematosus (SLE) and controls.

Methods: We investigated 163 SLE patients and 160 controls. Functional polymorphisms in 6 genes in the folate/homocysteine pathway were genotyped: 5,10-methylenetetrahydrofolate reductase (MTHFR) 677C>T, MTHFR 1298A>C, cystathionine ss-synthase (CBS) 844ins68, methionine synthase (MTR) 2756A>G, methionine synthase reductase (MTRR) 66A>G, thymidylate synthase (TYMS) 1494del6, and dihydrofolate reductase (DHFR) c.86+60_78.

Results: Homocysteine levels were higher in African American SLE patients than Caucasian patients and African American controls. Genotype distributions were significantly different in African American and Caucasian controls for 6 of the 7 polymorphisms. Genotype distributions for each polymorphism did not differ significantly between SLE patients and controls even after stratification by race. Glomerular filtration rate was strongly negatively correlated to homocysteine levels, and was therefore adjusted for as a covariate in the models of the effects of the polymorphisms on homocysteine levels. In SLE patients none of the 7 polymorphisms was associated with homocysteine concentrations. In Caucasian controls only MTHFR 677C>T and 1298A>C showed effects on homocysteine similar to what would be expected from the literature. There were no genotypic associations with median CAC scores in SLE patients or controls with and without stratification by race.

Conclusion: Polymorphisms in folate/homocysteine metabolizing enzymes do not predict higher homocysteine levels or CAC scores in patients with SLE.

Citing Articles

GC/MS and LC/MS serum metabolomic analysis of Chinese LN patients.

Wang W, Kou J, Long J, Wang T, Zhang M, Wei M Sci Rep. 2024; 14(1):1523.

PMID: 38233574 PMC: 10794181. DOI: 10.1038/s41598-024-52137-w.

The Search for Cancer Biomarkers: Assessing the Distribution of INDEL Markers in Different Genetic Ancestries.

Andrade R, Cavalcante G, Amador M, Moreira F, Khayat A, Assumpcao P Curr Issues Mol Biol. 2022; 44(5):2275-2286.

PMID: 35678683 PMC: 9164054. DOI: 10.3390/cimb44050154.

MTHFR polymorphisms (rs1801133) and systemic lupus erythematosus risk: A meta-analysis.

Zhou H, Yuan M Medicine (Baltimore). 2020; 99(40):e22614.

PMID: 33019481 PMC: 7535654. DOI: 10.1097/MD.0000000000022614.

Serum/plasma homocysteine levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis.

Sam N, Zhang Q, Li B, Li X, Wang D, Pan H Clin Rheumatol. 2020; 39(6):1725-1736.

PMID: 32090304 DOI: 10.1007/s10067-020-04985-w.

Folate/homocysteine metabolism and lung cancer risk among smokers.

Stanislawska-Sachadyn A, Borzyszkowska J, Krzeminski M, Janowicz A, Dziadziuszko R, Jassem J PLoS One. 2019; 14(4):e0214462.

PMID: 30939165 PMC: 6445430. DOI: 10.1371/journal.pone.0214462.

References

Harmon D, Woodside J, Yarnell J, McMaster D, Young I, McCrum E . The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM. 1996; 89(8):571-7. DOI: 10.1093/qjmed/89.8.571. View

Jacques P, Bostom A, Williams R, Ellison R, Eckfeldt J, Rosenberg I . Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996; 93(1):7-9. DOI: 10.1161/01.cir.93.1.7. View

Gaughan D, Kluijtmans L, Barbaux S, McMaster D, Young I, Yarnell J . The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis. 2001; 157(2):451-6. DOI: 10.1016/s0021-9150(00)00739-5. View

Brown K, Nackos E, Morthala S, Jensen L, Whitehead A, Von Feldt J . Monocyte chemoattractant protein-1: plasma concentrations and A(-2518)G promoter polymorphism of its gene in systemic lupus erythematosus. J Rheumatol. 2007; 34(4):740-6. View

Dekou V, Gudnason V, Hawe E, Miller G, Stansbie D, Humphries S . Gene-environment and gene-gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men. Thromb Haemost. 2001; 85(1):67-74. View

Schneede J, Refsum H, Ueland P . Biological and environmental determinants of plasma homocysteine. Semin Thromb Hemost. 2000; 26(3):263-79. DOI: 10.1055/s-2000-8471. View

Kealey C, Brown K, Woodside J, Young I, Murray L, Boreham C . A common insertion/deletion polymorphism of the thymidylate synthase (TYMS) gene is a determinant of red blood cell folate and homocysteine concentrations. Hum Genet. 2005; 116(5):347-53. DOI: 10.1007/s00439-004-1243-2. View

Lee A, Godfrey T, Rowley K, Karschimkus C, Dragicevic G, Romas E . Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus. Intern Med J. 2006; 36(4):237-43. DOI: 10.1111/j.1445-5994.2006.01044.x. View

Barbaux S, Kluijtmans L, WHITEHEAD A . Accurate and rapid "multiplex heteroduplexing" method for genotyping key enzymes involved in folate/homocysteine metabolism. Clin Chem. 2000; 46(7):907-12. View

10.

Pepe G, Vanegas O, Rickards O, Giusti B, Comeglio P, Brunelli T . World distribution of the T833C/844INS68 CBS in cis double mutation: a reliable anthropological marker. Hum Genet. 1999; 104(2):126-9. DOI: 10.1007/s004390050924. View

11.

Manzi S, Meilahn E, Rairie J, Conte C, Medsger Jr T, DAgostino R . Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997; 145(5):408-15. DOI: 10.1093/oxfordjournals.aje.a009122. View

12.

Afeltra A, Vadacca M, Conti L, Galluzzo S, Mitterhofer A, Ferri G . Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors. Arthritis Rheum. 2005; 53(3):452-9. DOI: 10.1002/art.21172. View

13.

Arad Y, Goodman K, Roth M, Newstein D, Guerci A . Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol. 2005; 46(1):158-65. DOI: 10.1016/j.jacc.2005.02.088. View

14.

Shi M, Caprau D, Romitti P, Christensen K, Murray J . Genotype frequencies and linkage disequilibrium in the CEPH human diversity panel for variants in folate pathway genes MTHFR, MTHFD, MTRR, RFC1, and GCP2. Birth Defects Res A Clin Mol Teratol. 2003; 67(8):545-9. DOI: 10.1002/bdra.10076. View

15.

Fredriksen A, Meyer K, Ueland P, Vollset S, Grotmol T, Schneede J . Large-scale population-based metabolic phenotyping of thirteen genetic polymorphisms related to one-carbon metabolism. Hum Mutat. 2007; 28(9):856-65. DOI: 10.1002/humu.20522. View

16.

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

17.

Von Feldt J, Scalzi L, Cucchiara A, Morthala S, Kealey C, Flagg S . Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum. 2006; 54(7):2220-7. DOI: 10.1002/art.21967. View

18.

Bruce I, Urowitz M, Gladman D, Ibanez D, Steiner G . Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum. 2003; 48(11):3159-67. DOI: 10.1002/art.11296. View

19.

Ranganathan P, Culverhouse R, Marsh S, Ahluwalia R, Shannon W, Eisen S . Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. Pharmacogenomics. 2004; 5(5):559-69. DOI: 10.1517/14622416.5.5.559. View

20.

Graham I, Daly L, Refsum H, Robinson K, Brattstrom L, Ueland P . Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997; 277(22):1775-81. DOI: 10.1001/jama.1997.03540460039030. View